To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation
PHASE4CompletedINTERVENTIONAL
Enrollment
200
Participants
Timeline
Start Date
September 30, 2003
Conditions
Atrial Fibrillation
Interventions
DRUG
Flecainide controlled release
Trial Locations (1)
59037
Hopital Cardiologique, Service de Cardiologique CHR de Lille, Lille
All Listed Sponsors
lead
MEDA Pharma GmbH & Co. KG
INDUSTRY
NCT00189319 - To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation | Biotech Hunter | Biotech Hunter